<DOC>
	<DOCNO>NCT00039884</DOCNO>
	<brief_summary>This clinical trial ( type research study ) design describe efficacy ( effectiveness ) toxicity ( safety ) new medical treatment , NESP ( Novel Erythropoiesis Stimulating Protein ) . This study offer patient cervical cancer undergo combination chemotherapy radiation . This treatment may lower red blood cell . The use NESP may stimulate body produce red blood cell . Our hypothesis high red blood cell beneficial patient treatment cervical cancer .</brief_summary>
	<brief_title>Will Radiation/Chemotherapy Treatment Cervical Cancer Work Better With Medication That May Improve Anemia ?</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Consent form complete sign Hemoglobin 913 g/dL Life expectancy least 4 month Karnofsky Performance Status =/ &gt; 70 No evidence hemolysis , GI bleeding , bleed due recent surgery Adequate renal liver function</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2002</verification_date>
	<keyword>Cervical cancer</keyword>
</DOC>